Modalis Therapeutics Corporation
Notice on Monthly Exercise Status of the 19th Stock Acquisition Rights Issued by Third-Party Allotment (with Exercise Price Adjustment Clause)
Published the monthly exercise status for the 19th stock acquisition rights for October 2026 issued by third-party allotment. Of 2,320,000 shares delivered, 23,200 stock acquisition rights were exercised, representing 9.7% of the total issued, and unexercised rights at month-end amounted to 43,800. Compliance with exercise restrictions shows an exercise ratio of 2.4%, with 96,334,098 listed shares.
Key Figures
- Number of shares delivered: 2,320,000 shares
- Number of stock acquisition rights exercised: 23,200 cases
- Total issued: 240,000 cases
- Unexercised rights (end of previous month): 67,000 cases
- Unexercised rights (month-end): 43,800 cases
- Exercise ratio: 2.4%
- Listed shares: 96,334,098 shares
- Outstanding shares (target month): 113,634,098 shares (of which treasury stock 64 shares)
AI要約
Overview of the Event
This publication reports the monthly exercise status for October 2026 of the 19th stock acquisition rights issued by third-party allotment. The number of shares delivered in the target month was 2,320,000 shares; 23,200 stock acquisition rights were exercised during the month, representing 9.7% of the total issued. Unexercised rights at the end of the previous month were 67,000 cases, and unexercised rights at month-end were 43,800 cases. The compliance with exercise restrictions shows an exercise ratio of 2.4%, and the number of listed shares is 96,334,098 shares.
Impact on Investors and Background
Monthly exercise status of stock acquisition rights can be an indicator of dilution progression; however, the current exercise ratio is a single-digit percentage of total issued rights, and the near-term impact on share dilution is considered limited. Exercise dates are not specified, and details of individual transactions are limited to the published data. Continued disclosures will need to be monitored to assess exercise trends and impacts on capital structure.
Modalis Therapeutics Corporation
Company overview · Stock price · Financial data · All IR
